Onkologie. 2010:4(2):128-129

Sorafenib je účinný v sekvenční terapii metastatického renálního karcinomu

Axel S Merseburger, Annika Simon, Sandra Waalkes, Markus A Kuczyk
Hannover Medical School, Department of Urology and Urological Oncology, Hannover, Německo

Published: May 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Merseburger AS, Simon A, Waalkes S, Kuczyk MA. Sorafenib je účinný v sekvenční terapii metastatického renálního karcinomu. Onkologie. 2010;4(2):128-129.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kruck S, Merseburger AS, Gakis G, Kramer MW, Stenzl A, Kuczyk MA. An update on the medical therapy of advanced metastatic renal cell carcinoma. Scand. J. Urol. Nephrol. 2008; 42(6): 501-506. Go to original source... Go to PubMed...
    2. Bastien L, Culine S, Paule B, Ledbai S, Patard JJ, de la Taille A. Targeted therapies in metastatic renal cancer in 2009. BJU Int. 2009; 103(10): 1334-1342. Go to PubMed...
    3. Mills EJ, Rachlis B, O'Regan C, Thabane L, Perri D. Metastatic renal cell cancer treatments: an indirect comparison meta-analysis. BMC Cancer 2009; 9: 34. Go to original source... Go to PubMed...
    4. Tamaskar I, Garcia JA, Elson P, et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J. Urol. 2008; 179(1): 81-86. Go to original source... Go to PubMed...
    5. Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 2009; 115(1): 61-67. Go to original source... Go to PubMed...
    6. Eichelberg C, Heuer R, Chun FK, et al. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur. Urol. 2008; 54(6): 1373-1378. Go to original source... Go to PubMed...
    7. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the Phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol. 2009; 27(20): 3312-3318. Go to original source... Go to PubMed...
    8. Shepard DR, Rini BR, Garcia J, et al. A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab. J. Clin. Oncol. 26(5123), (2008) (Abstract). Go to original source...
    9. Sepulveda J, Maroto P, Andres R, et al. Sorafenib as a second-line and sequential therapy for patients with metastatic renal cell carcinoma (mRCC): analysis for safety and activity on sunitinib progressive pts. ASCO Meeting Abstracts 26(15 Suppl.) (2008) Abstract 16100). Go to original source...
    10. Zimmermann K, Schmittel A, Steiner U, et al. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 2009; 76(5): 350-354. Go to original source... Go to PubMed...
    11. Sablin MP, Negrier S, Ravaud A, et al. Sequential sorafenib and sunitinib for renal carcinoma. J. Urol. 2009; 182: 29-34. Go to original source... Go to PubMed...
    12. Richter S, Pfister D, Thüer D, Engelmann UH, Heidenreich A. Second-line treatment of progressive metastatic renal cell cancer with temsirolimus following first-line therapy with sunitinib or sorafenib. Onkologie 2008; 31(Suppl. 4): V684.
    13. Choueiri TK, Brick AJ, McDermott S, et al. Treatment and dosing patterns for angiogenesis inhibitor (AIS) therapies in patients with metastatic renal cell carcinoma (MRCC). Ann. Oncol. 2008; 19(Suppl. 8): 593P.
    14. Porta C, Procopio G, Sabbatini R, et al. Retrospective analysis of the sequential use of sorafenib and sunitinib in patients with advanced renal cell carcinoma (RCC). Eur. J. Urol. 8 (Suppl. 4), 183 (2009) (Abstract 252). Go to original source...
    15. Beck J, Bajetta E, Escudier B, et al. A large open-label non-comparative Phase III study of the multi-targeted kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma. Eur. J. Cancer 5(4 Suppl.), 300 (2007) (Abstract 4506). Go to original source...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.